TI-23-020: Comprehensive Opioid Recovery Centers
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Substance Abuse and Mental Health Services Adminis notices from 2023.
Substance Abuse and Mental Health Services Adminis offered grants of up to $850,000 to the applicants described in the notice. It expected to make about 2 awards worth $1.4 million in total. Applications closed on May 16, 2023.
From the official notice on Grants.gov, last changed March 17, 2023. Checked November 7, 2026.
- Award ceiling$850,000
- Total funding$1.4 million
- Expected awards2
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| TI-26-013 | July 14, 2026 | Closed July 29, 2026 | Closed |
Key dates
| Posted | March 17, 2023 |
|---|---|
| Deadline | May 16, 2023 |
| Archived by Grants.gov | June 15, 2023 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Eligibility is statutorily limited to public and private nonprofit entities which provide treatment and other services for individuals with substance use disorders.
Is this a realistic fit?
- Past Opioid STR awards averaged $6.2 million; this notice allows up to $850,000 per award.
- Most of the program's money (92% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
The purpose of the program is to establish or implement comprehensive treatment and recovery centers which provide a full spectrum of treatment, harm reduction, and recovery support services to address the opioid epidemic and ensure access to all three FDA approved medications for Opioid Use Disorder (MOUD).
Who has won Opioid STR grants before
From fiscal 2021 to 2025, Opioid STR (93.788) awarded $2.1 billion across 336 grant awards, an average of $6.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Ohio Department Mental Health | Ohio | 2 | $154 million |
| Pennsylvania Department of Drug and Alcohol Programs | Pennsylvania | 2 | $138 million |
| California Department of Health Care Services | California | 1 | $108 million |
| Maryland Department of Health | Maryland | 2 | $105 million |
| Delaware Department of Health and Social Services | Delaware | 2 | $104 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is TI-23-020 still open?
No. It closed on May 16, 2023.
Who can apply for Comprehensive Opioid Recovery Centers?
Substance Abuse and Mental Health Services Adminis accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Comprehensive Opioid Recovery Centers?
Closed May 16, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $850,000 each. About $1.4 million in total across about 2 awards.
Who has won Opioid STR grants before?
The largest recipients over five fiscal years were Ohio Department Mental Health, Pennsylvania Department of Drug and Alcohol Programs, California Department of Health Care Services. The program made 336 awards worth $2.1 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)